The Drug Enforcement Administration announced Wednesday it’s making research into the non-intoxicating cannabis compound cannabidiol (CBD) easier, but advocates for legal access to what appears an effective treatment for epilepsy say the change doesn’t go nearly far enough.
The policy tweak will allow researchers to modify or expand existing federally approved CBD studies without having to undergo a potentially time-consuming review by the DEA, which along with the Food and Drug Administration acts as a gatekeeper to cannabis research.
DEA spokeswoman Barbara Carreno says there currently are 330 active cannabis studies, with more than 70 looking at CBD, a handful of which are clinical studies that may benefit from the new policy.
“If [researchers] adjusted their protocol and the amount they needed, they needed to change their registration,” Carreno explains.
Click here to read the complete article
Steven Nelson ~ U.S. News & World Report ~
